What Does It Mean That Most Cannabis Products Are Unlicensed in the UK?

The cannabis conversation in the UK has transformed significantly since 2018, but a key phrase often trips up patients and even some healthcare professionals alike: unlicensed cannabis medicine. What does it really mean when we say most cannabis products are unlicensed in the UK? And how does that affect who can prescribe them, who can access them, and what it means for safety and quality?

This post breaks down the essentials—translating complicated regulations into plain English—and explores the landscape shaped by the 2018 rescheduling, NHS funding rules, and specialist prescribing restrictions. We’ll also signpost patient-friendly resources like medicalcannabis.co.uk and releaf.co.uk to help you better understand your options.

Background: The 2018 Rescheduling Changed Everything (But Not Quite Everything)

Before November 2018, cannabis-based products for medicinal use were categorised as Schedule 1 drugs in the UK, meaning no recognised medical value and thus no legal prescribing allowed on the NHS vergemagazine.co or privately. On 1 November 2018, the UK government rescheduled cannabis-based products for medicinal use to Schedule 2, a significant regulatory shift allowing specialist doctors to prescribe certain cannabis medicines legally.

Key change: cannabis medicines moved from 'no legal prescribing allowed' to 'specialist doctor can prescribe under certain conditions.'

However, the rescheduling did NOT mean that cannabis medicines instantly became widely available or fully licensed products like paracetamol or antibiotics. In fact, almost all cannabis-based products remained—and still remain— unlicensed medicines in the UK.

Licensed medicine: A medicine approved by the Medicines and Healthcare products Regulatory Agency (MHRA) after detailed assessments of safety, quality, and efficacy.
Unlicensed medicine: A medicine without formal MHRA approval but used when licensed options are unsuitable or unavailable, often under specialist supervision.

So when we say 'most cannabis products are unlicensed in the UK,' it means there is no standardized MHRA approval for their use for most indications. Instead, clinicians prescribe them under specific frameworks that involve careful risk assessments.

What Does 'Unlicensed Cannabis Medicine' Mean in Practice?

From a patient viewpoint, 'unlicensed cannabis medicine' means the product you might receive has not gone through the full conventional approval process that most medicines undergo. This does not mean it’s illegal—quite the opposite since specialist prescribing for cannabis is legal since 2018—but it does have important implications for how these medicines are prescribed, accessed, and funded.

Implications of Unlicensed Status:

Safety and Quality Assessment: While unlicensed medicines are not MHRA-approved, they are made to pharmaceutical standards, often sourced from specialised manufacturers with strict quality controls. Clinicians must weigh the evidence and monitor patients carefully.
NHS Funding: NHS funding guidance (accessible for example via NICE or NHS England update documents) makes clear that unlicensed cannabis medicines are generally not routinely funded on the NHS. This means patients may face significant private costs if wishing to access these treatments.
Specialist Prescribing Only: Only doctors with appropriate specialist qualifications and knowledge can prescribe unlicensed cannabis medicines; general practitioners (GPs) do not have the authority to do so independently.

In short: these medicines are legal when prescribed by specialists, but usually not paid for by the NHS and require careful clinical oversight.

NHS Prescribing Guidance on Cannabis: What Clinicians See

To clarify how unlicensed cannabis medicines fit into NHS practice, the National Institute for Health and Care Excellence (NICE), NHS England, and other bodies have issued guidance documents to help clinicians navigate prescribing decisions.

Here are some highlights of what "NHS prescribing guidance cannabis" says in plain English:

Specialist Only: Cannabis medicines can only be prescribed by specialists in certain fields (like neurology, pain management, paediatrics) who have appropriate expertise.
Considered After Other Treatments: Prescribing these medicines is reserved for cases where licensed treatments have failed or are not suitable.
Safety and Monitoring: Because unlicensed cannabis medicines do not have the same level of clinical trial data as licensed medicines, prescribers must monitor patients closely for side effects and effectiveness.
NHS Funding Restrictions: Due to limited evidence on efficacy and cost-effectiveness, NHS commissioning bodies are cautious and generally do not fund cannabis medicines except in exceptional cases or approved clinical trials.

This cautious position reflects legitimate concerns around the safety, quality, and efficacy assessment of unlicensed cannabis products. It is not a ban, but an emphasis on the responsibility to ensure patient safety and prudent use of NHS resources.

Private Prescribing and the Role of Specialist Clinics

Because the NHS largely does not fund unlicensed cannabis medicines, many patients turn to private prescribers if seeking these treatments. Specialist clinics—many listed on medicalcannabis.co.uk—offer consultations and prescriptions, but this route involves:

Paying for the consultation and medicine out-of-pocket (prices vary and no standard prices are set—note that no specific prices were stated in the scraped content; if a price is mentioned in future sources, quote it exactly and attribute it.)
Being assessed by a specialist who will determine if cannabis-based medicines are appropriate given medical history and previous treatments
Ongoing follow-up to monitor efficacy and side effects

The site releaf.co.uk provides an excellent patient-friendly explainer about what to expect from a private cannabis clinic and common patient questions.

Why Is the NHS Cautious About Funding Unlicensed Cannabis Medicines?

The question on many lips is: if these cannabis medicines are legal to prescribe, why won't the NHS just pay for them?

The answer lies in the rigour demanded in healthcare commissioning. The NHS requires clear evidence of :

Safety: That the medicine’s benefits outweigh potential harms.
Quality: That the products are manufactured to consistent pharmaceutical standards.
Efficacy: That the medicine works better than placebo or existing treatments.

Given that most cannabis products in the UK are unlicensed, clinical trial evidence for specific formulations, dosages, and indications is limited. Systematic reviews, including NICE evidence summaries, have highlighted gaps, making it difficult to approve routine NHS funding. Many specialists and patient advocates share the hope that ongoing research will lead to licensed products and better access in the future.

Summary Table: What 'Unlicensed Cannabis Medicine' Means in the UK

Aspect Explanation Legal Status Legal to prescribe by specialists since 2018 rescheduling; not illegal. Licence Status Most cannabis products do not have MHRA licence; hence 'unlicensed medicine.' Prescribing Rules Specialist-only prescribing; GPs cannot initiate prescriptions. NHS Funding Generally not routinely funded; often only private funding available. Safety & Quality Products meet pharmaceutical manufacturing standards but lack robust MHRA licensing data. Efficacy Evidence is limited and condition-dependent; specialist judgement required.

Final Thoughts: Navigating the Cannabis Medicine Landscape in the UK

Understanding that most cannabis products remain unlicensed clarifies a lot about how access works in practice. It's a landscape defined by specialist prescribing, patient safety, NHS funding caution, and ongoing research. While the 2018 rescheduling opened the door to legal prescribing, it did not turn cannabis medicines into conventional, off-the-shelf treatments.

For patients seeking options, trusted directories like medicalcannabis.co.uk and explainer sites such as releaf.co.uk can help you navigate your pathway and understand whether these products might be appropriate for you.

Remember: If you're curious about medical cannabis, your first step should always be to discuss it with a specialist who can advise based on your specific medical needs and current evidence.